PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Publications
Contact Us
Log In
You need to enable JavaScript to run this app page.
Leukemia
TCH-AML002
Model Details
Patient
PDX Model
Histology
Metastasis
Patient Treatment
Patient Information for Model: TCH-AML002
Contact Model Developer
Model Contact
Model: TCH-AML002
Model Contact: Michele Redell
Institution: TCH Leukemia PDX Program
Email:
mlredell@texaschildrens.org
Patient Information
Clinical Timeline
Clinical Information at Collection
Clinical Biomarkers/Mutations
Model Information for Model: TCH-AML002
Model Details - Initial Implantation of Patient Tissue
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Histology Information for Model: TCH-AML002
There are no histology images for this model.
Metastasis Information for Model: TCH-AML002
Patient
PDX
Abdomen
BM
Central Nervous System
Face
Gingiva
Kidney
Kidneys
L cheek
Leg
Liver
Lymph node
Orbital chloroma
PB
Pancreas
Periorbital
Retinas
Skin
Skull base
Spine
Spleen
Stomach
Tail
Temporal bone
Testis
Tongue
periorbital chloroma
sacrum
Patient Treatment Information for Model: TCH-AML002
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
Measurable Residual Disease
10
Cytarabine/Idarubicin
De Novo
20.06
Unknown
Induction Failure
15
Cytarabine/Fludarabine
Refractory
20.25
Unknown
Residual Disease
20
clo/topotecan/vinorelbine/thiotepa
Refractory
20.37
Unknown
Residual Disease
25
azacitidine/venetoclax
Refractory
20.54
Unknown
30
venetoclax
Refractory
20.66
Unknown
Remission
.16%
50
decitabine/venetoclax then DLI
Relapse
21.3
Unknown
Relapse
14%
60
decitabine/venetoclax then DLI
Relapse
21.4
Unknown
Relapse
4%
Please wait...
